Researchers at the University of Alabama at Birmingham have shown — for the first time — that established lung fibrosis can be reversed using a drug treatment that targets cell metabolism.
This novel finding, reported in the journal Nature Medicine, is important because, despite significant advances to reveal the pathological mechanisms of persistent fibrosis, effective treatment interventions are lacking.
Pulmonary fibrosis can develop after lung injuries like infections, radiation or chemotherapy, or it can have an unknown cause, as in idiopathic pulmonary fibrosis, or IPF. IPF is a progressive, and ultimately fatal, lung disorder that strikes more than 150,000 patients a year in the United States and more than 5 million worldwide.
In experiments using lung tissues from patients with IPF, mouselung fibroblasts and a murine model of lung fibrosis, a team led by Jaroslaw Zmijewski, Ph.D., and Victor Thannickal, M.D., showed the reversal of lung fibrosis and the underlying cellular mechanisms affected by the drug treatment.
Zmijewski and Thannickal are, respectively, associate professor and professor in the UAB Department of Medicine. Zmijewski serves as research director for the Translational Program in ARDS. Thannickal holds the Ben Vaughan Branscomb Chair of Medicine in Respiratory Disease and is director of the UAB Division of Pulmonary, Allergy and Critical Care Medicine.
|Activation of AMPK in myofibroblasts from lungs of humans with IPF, using the drug metformin or another activator called AICAR, led to lower fibrotic activity. AMPK activation also enhanced the production of new mitochondria, the organelles in cells that produce energy, in the myofibroblasts, and it normalized the cells’ sensitivity to apoptosis.|
Interestingly, the drug that accelerated the resolution of lung fibrosis is metformin, which is a safe and widely used agent for non-insulin-dependent diabetes.
The research focused on AMP-activated protein kinase (AMPK), an enzyme that senses energy state in the cell and regulates metabolism. Zmijewski, Thannickal and colleagues found that AMPK activity was lower in myofibroblast cells within fibrotic regions of human lung tissue from IPF patients. Myofibroblasts deposit extracellular collagen fiber as part of the fibrosis process. These myofibroblasts were metabolically active and were resistant to the programmed cell death called apoptosis, a natural process that removes more than 50 billion damaged or aged cells in adults each day.
Activation of AMPK in myofibroblasts from lungs of humans with IPF, using the drug metformin or another activator called AICAR, led to lower fibrotic activity. AMPK activation also enhanced the production of new mitochondria, the organelles in cells that produce energy, in the myofibroblasts, and it normalized the cells’ sensitivity to apoptosis.
Using a mouse model for lung fibrosis elicited by the anti-cancer drug bleomycin, the research team found metformin treatment, starting three weeks after lung injury and continuing for five weeks, accelerated the resolution of well-established fibrosis. Such resolution was not apparent in AMPK-knockout mice, showing that the effect of metformin was AMPK-dependent.
“Together, our studies support the concept that AMPK may function as a critical metabolic switch in promoting resolution of established fibrosis by shifting the balance from anabolic to catabolic metabolism,” the researchers wrote. “Additionally, we provide proof-of-concept that activation of AMPK by metformin or other pharmacologic agents that activate these pro-resolution pathways may be a useful therapeutic strategy for progressive fibrotic disorders.”
Anabolic metabolism builds up molecules in the cell from smaller units, while catabolic metabolism tears larger molecules into smaller pieces.
Learn more: Metformin reverses established lung fibrosis
The Latest on: Pulmonary fibrosis
via Google News
The Latest on: Pulmonary fibrosis
- New Indication OK'd for Lung Drug Ofevon September 6, 2019 at 1:27 pm
Previously approved to treat idiopathic pulmonary fibrosis, nintedanib becomes the first treatment specifically indicated for SSc-ILD, for which few options are available. "Patients suffering from ...
- FDA approves first treatment for patients with rare type of lung diseaseon September 6, 2019 at 12:25 pm
Ofev was originally approved in 2014 for adult patients with idiopathic pulmonary fibrosis (IPF), which is another interstitial lung condition. Ofev received Priority Review designation ...
- Pulmonary Fibrosis support group meets second Tuesday of every monthon September 5, 2019 at 6:33 pm
September is Pulmonary Fibrosis Awareness Month. A local support group meets on the second Tuesday of every month at the Cherokee Mills Building on Sutherland Avenue in Knoxville. The meetings start ...
- September marks Pulmonary Fibrosis Awareness Monthon September 5, 2019 at 1:21 pm
September has been designated Pulmonary Fibrosis Awareness Month — a time during which researchers and clinicians aim to improve the public’s knowledge about the disease. This September, efforts ...
- Trevi Therapeutics to Participate in Panel Discussion at BTIG Pain / Pruritus Management Forumon September 5, 2019 at 1:05 pm
Trevi is currently developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and levodopa-induced dyskinesia (LID) in patients ...
- Three Lakes Partners And Pulmonary Fibrosis Foundation Partner In Fight Against Pulmonary Fibrosison September 4, 2019 at 8:38 am
CHICAGO, Sept. 4, 2019 /PRNewswire/ -- The Pulmonary Fibrosis Foundation (PFF) and Three Lakes Partners today marked September's National Pulmonary Fibrosis Awareness Month with the announcement ...
- Prognosis of non-small-cell lung cancer in patients with idiopathic pulmonary fibrosison August 29, 2019 at 2:12 am
The risk of lung cancer is higher in idiopathic pulmonary fibrosis (IPF) because both conditions share common risk factors. However, no standard treatment modality for LC in IPF exists due to rare ...
- Idiopathic Pulmonary Fibrosis (IPF) Market Insights, Epidemiology and Forecast, 2028on August 28, 2019 at 8:45 am
DUBLIN, Aug. 28, 2019 /PRNewswire/ -- The "Idiopathic Pulmonary Fibrosis (IPF) - Market Insights, Epidemiology and Market Forecast - 2028" drug pipelines has been added to ResearchAndMarkets.com's ...
- Pulmonary fibrosis: All you need to know about it and treatmenton August 25, 2019 at 11:13 pm
Your sudden weight loss is bothering you? Then, it's time to consult your doctor as you may be suffering from pulmonary fibrosis Do you often feel fatigued? Is your constant coughing snatching away ...
via Bing News